Primary Outcome Measures
Overall Response Rate [Time Frame: From the start of the treatment until disease progression/recurrence, up to approximately 5 years] [Designated as safety issue: ]
Number of participants with grade 3, 4 and 5 adverse events [Time Frame: From the start of treatment until 30 days after the last dose of a study drug, up to approximately 5 years] [Designated as safety issue: ]
Secondary Outcome Measures
Progression Free Survival [Time Frame: From the date of randomization until disease progression or death due to any cause, up to approximately 5 years] [Designated as safety issue: ]
Disease Control Rate [Time Frame: From the start of the treatment until disease progression/recurrence, up to approximately 5 years] [Designated as safety issue: ]
Duration of Response [Time Frame: From the first documented response until the time of disease progression, up to approximately 5 years] [Designated as safety issue: ]
Overall Survival [Time Frame: From the date of randomization until the time of death, up to approximately 10 years] [Designated as safety issue: ]
Mechanisms of response and resistance to dabrafenib, trametinib, and PDR001 [Time Frame: Pre treatment and day 15] [Designated as safety issue: ]